BMGL (Basel Medical Group) Research & Development: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMGL Basel Medical Group Ltd BMGL
17 GF Score
Price $5.70
! 3 Warning Signs
View Full Analysis

What is Basel Medical Group Research & Development?

Basel Medical Group BMGL -7.17% 17 Research & Development is $0.00 Mil as of Dec. 2025. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Basel Medical Group's Research & Development for the six months ended in Dec. 2025 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Basel Medical Group  (NAS:BMGL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Basel Medical Group Research & Development Related Terms

Basel Medical Group Research & Development Historical Data

* Premium members only.

The historical data trend for Basel Medical Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basel Medical Group Research & Development Chart

Basel Medical Group Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Research & Development
0.00 0.00 0.00 0.00

Basel Medical Group Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
BMGL
17GF Score
Basel Medical Group Ltd BMGL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basel Medical Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Basel Medical Group (BMGL) has a Research & Development of $0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Basel Medical Group and its competitors.
Is Basel Medical Group's Research & Development too high?
Basel Medical Group's current Research & Development is $0.00 Mil. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's Research & Development compare to AMS and HLYK?
Basel Medical Group's Research & Development of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Basel Medical Group and its competitors. Basel Medical Group's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current Research & Development is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Basel Medical Group Business Description

Address 6 Napier Road, Unit No. 02-10/11, Gleneagles Medical Centre, Singapore, SGP, 258499
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score

Get the complete analysis for BMGL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.70
Price